← Research library

Colorectal cancer review of thymopentin and other thymic preparations

Review of earlier studies · 2026

What was studied
30 controlled studies across multiple thymic preparations, 2,514 participant records. Two thymopentin-plus-XELOX reports contributed 130 records to the functional-status estimate, with 40/40 and 25/25 in the respective studies.
Main finding
Karnofsky Performance Status · Pooled mean difference +4.35 points (95% CI 1.90–6.80) from two trials, rated very low certainty.

Reported findings and study design

Reported findings

The two relevant comparisons used capecitabine plus oxaliplatin (XELOX), with or without thymopentin 10 mg IM daily for 15 days per course over four courses, as reported in Table 1.

Population or model 30 controlled studies across multiple thymic preparations, 2,514 participant records. Two thymopentin-plus-XELOX reports contributed 130 records to the functional-status estimate, with 40/40 and 25/25 in the respective studies.

Dose, route and schedule

The two relevant comparisons used capecitabine plus oxaliplatin (XELOX), with or without thymopentin 10 mg IM daily for 15 days per course over four courses, as reported in Table 1.

Protocol source ↗ · Published review, Tables 1–3 and Figures 6–7. The two thymopentin reports are represented here by the review’s extraction.

Results · Published review, Tables 1–3 and Figures 6–7. The two thymopentin reports are represented here by the review’s extraction.
MeasureResultComparison, timing and statistics
Karnofsky Performance StatusPooled mean difference +4.35 points (95% CI 1.90–6.80) from two trials, rated very low certainty.
Hand–foot syndromePooled RR 0.37 (95% CI 0.17–0.82) from the same two studies, rated low certainty. Neurotoxicity, granulocytopenia and gastrointestinal reactions were inconclusive.
One-year survivalOne 80-person trial contributed RR 1.52 (95% CI 1.18–1.95), rated very low certainty. There was no pool of independent survival estimates.

The review flagged identical arm-level standard deviations across the two performance-status reports and could not confirm their full independence. These are review totals across several preparations and are not additional patients. The review concluded that the evidence was insufficient for routine clinical use.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The review flagged identical arm-level standard deviations across the two performance-status reports and could not confirm their full independence. These are review totals across several preparations and are not additional patients. The review concluded that the evidence was insufficient for routine clinical use.

Source details

Systematic review

Published review, Tables 1–3 and Figures 6–7. The two thymopentin reports are represented here by the review’s extraction.

Sources checked

Added to the library

Citation

ReviewFull text available

G. Zhang, Y. Zhou, T. Sun, X. Chen, Y. Zheng. Colorectal cancer review of thymopentin and other thymic preparations Frontiers in Oncology 16, 1957041.

Study source ↗ · DOI 10.3389/fonc.2026.1957041 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards